Aster DM Quality Care Limited (ASTERDM) — key facts
NSE-listed · Healthcare. Data as of 11 Nov 2026 (IST) from InvestSights.
Last close: ₹733.4 (-2.13% day change)
Key ratios
- P/E ratio
- 97.4
- P/B ratio
- 7.55
- ROE (%)
- 8.48
- ROCE (%)
- 8.93
- Debt/Equity
- 0.49
- Dividend yield (%)
- 0.15
- Market cap (₹ Cr)
- 37,913.32
Forensic checks
Piotroski F-Score: 5/9 · Altman Z-Score: 6.03 · Beneish M-Score: -2.1
InvestSights quality score
52.1/100 — Average (descriptive data-driven composite; not a recommendation)
Management guidance track record
- EBITDA margin: guided 21%, delivered 21.7% (Q4 FY26) — exceeded guidance
- ALOS: guided 3.1–3.2days, delivered 3.1days (FY26) — met guidance
Latest earnings call (Q2 FY27)
AI summary: The most important signal is that management is positioning the merger as an execution and capital-productivity programme rather than merely a scale transaction. The combined platform reported pro forma revenue of ₹9,273 crore, operating EBITDA of ₹2,013 crore and margin of 21.7%, while management outlined plans to add 4,200 beds, with 53% coming through brownfield expansion.…
Full analysis on InvestSights
InvestSights is an analytics platform and is not SEBI-registered as a Research Analyst or Investment Adviser. All figures are educational, descriptive data — not investment advice. Consult a SEBI-registered adviser before investing.